Saturday, June 4, 2016

Drug racket preying on cancer patients

From SL Mirror
A substandard cancer drug imported from China is being administered to children suffering from leukemia at the Maharagama Cancer Hospital.
A stock of the drug, named Oncaspar, is being stocked at the hospital even at the present.
The stock, amounting to Rs. 30 million, has been imported from China by OMACX Health Care (Pvt.) Ltd.
The company has registered a new partner company named Medmart Pharma (Pvt) Ltd on July 18, 2013 and is being functioned by those at OMACX Health Care.
However, this Chinese drug is not even used in China and no known clinical trials have been done.
The authentic Oncaspar drug is produced in the US. It is a patented drug and the only product that has proper clinical trials and the WHO/GMP certification.
Although the tender to import this authentic drug was secured by S J Enterprises. However, it was later secured by OMACX Health Care.
The Chinese drug is not even registered in the National Drug Regulatory Authority and it is said that there are no laboratory to check the authenticity of the drug.

No comments:

Post a Comment